Holders — by stockHoldings — by fund
Rosalind Advisors, Inc.
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001622627
$269.2M
disclosed book value
35
positions
15.4%
largest position share
Positions, as of 2026-06-30
top 35 of 35 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | DCTHDELCATH SYSTEMS, INC. | 3.3M | $41.6M | 15.4% |
| 2 | FENCFENNEC PHARMACEUTICALS INC | 3.2M | $34.3M | 12.7% |
| 3 | XERSXERIS BIOPHARMA HOLDINGS INC | 2.9M | $23.0M | 8.6% |
| 4 | SVRASAVARA INC | 3.2M | $19.6M | 7.3% |
| 5 | VSTMVERASTEM INC | 4.0M | $15.2M | 5.7% |
| 6 | XFORX4 PHARMACEUTICALS INC | 3.2M | $15.0M | 5.6% |
| 7 | EYPTEYEPOINT PHARMACEUTICALS INC | 988,230 | $14.1M | 5.2% |
| 8 | HELPCYBIN INC | 2.0M | $12.9M | 4.8% |
| 9 | VORVOR BIOPHARMA INC | 648,600 | $11.9M | 4.4% |
| 10 | PCVXVAXCYTE INC | 200,000 | $11.6M | 4.3% |
| 11 | MEDIWOUND LTD | 749,054 | $11.0M | 4.1% |
| 12 | CLDXCELLDEX THERAPEUTICS INC | 200,000 | $7.4M | 2.8% |
| 13 | BCRXBIOCRYST PHARMACEUTICALS INC | 721,504 | $7.2M | 2.7% |
| 14 | PROFPROFOUND MEDICAL CORP | 828,118 | $5.5M | 2% |
| 15 | TLPHTALPHERA INC | 5.2M | $5.3M | 2% |
| 16 | AVIRATEA PHARMACEUTICALS INC | 1.1M | $5.0M | 1.8% |
| 17 | MYOMYOMO INC | 3.6M | $3.8M | 1.4% |
| 18 | OVIDOVID THERAPEUTICS INC | 1.1M | $3.0M | 1.1% |
| 19 | NRXSNEURAXIS INC | 508,055 | $3.0M | 1.1% |
| 20 | ABVXABIVAX SA | 20,869 | $2.8M | 1% |
| 21 | NSPRINSPIREMD INC | 3.9M | $2.7M | 1% |
| 22 | REGENTIS BIOMATERIALS LTD | 701,685 | $2.5M | 0.9% |
| 23 | SELLAS LIFE SCIENCES GROUP INCPUT | 568,700 | $2.3M | 0.9% |
| 24 | POLYPID LTD | 389,455 | $2.0M | 0.7% |
| 25 | BFRIBIOFRONTERA INC | 1.3M | $1.2M | 0.4% |
| 26 | KURAKURA ONCOLOGY INC | 100,000 | $1.1M | 0.4% |
| 27 | SPRBSPRUCE BIOSCIENCES INC | 20,000 | $1.1M | 0.4% |
| 28 | AQSTAQUESTIVE THERAPEUTICS INC | 250,000 | $1.0M | 0.4% |
| 29 | OKURONKURE THERAPEUTICS INC | 150,000 | $684,000 | 0.3% |
| 30 | PEPGPEPGEN INC | 350,000 | $630,000 | 0.2% |
| 31 | CG ONCOLOGY INCCALL | 31,000 | $375,100 | 0.1% |
| 32 | EYEPOINT PHARMACEUTICALS INCCALL | 50,300 | $130,780 | 0% |
| 33 | ISHARES TRPUT | 500,000 | $110,000 | 0% |
| 34 | SPDR SERIES TRUSTPUT | 140,600 | $35,150 | 0% |
| 35 | TENAX THERAPEUTICS INCPUT | 6,200 | $13,950 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.